<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003754</url>
  </required_header>
  <id_info>
    <org_study_id>98-088</org_study_id>
    <secondary_id>CDR0000066878</secondary_id>
    <secondary_id>MSKCC-98088A(4)</secondary_id>
    <secondary_id>NCI-G99-1498</secondary_id>
    <nct_id>NCT00003754</nct_id>
  </id_info>
  <brief_title>Thalidomide and Cyclophosphamide in Treating Children With Recurrent or Refractory Childhood Cancers</brief_title>
  <official_title>A Phase II Study of Thalidomide and Cyclophosphamide in Patients With Recurrent or Refractory Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Thalidomide may kill tumor cells by stopping the growth of new blood vessels to&#xD;
      the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining thalidomide with chemotherapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining thalidomide and&#xD;
      cyclophosphamide in treating children who have recurrent or refractory childhood cancers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the efficacy and toxic effects of thalidomide and cyclophosphamide&#xD;
      in patients with recurrent or refractory pediatric malignancies.&#xD;
&#xD;
      OUTLINE: Patients receive oral thalidomide 4 times daily. Cyclophosphamide is administered IV&#xD;
      over 1 hour once every 4 weeks, beginning on the same day as thalidomide. Treatment continues&#xD;
      in the absence of unacceptable toxicity or disease progression. Tumor response is assessed&#xD;
      every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 45-80 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1998</start_date>
  <completion_date type="Actual">July 2001</completion_date>
  <primary_completion_date type="Actual">July 2001</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically or cytologically proven pediatric malignancy,&#xD;
        except when there is appearance consistent with brainstem tumor on MRI, a tumor marker&#xD;
        positive for germ cell tumor, or ophthalmologic diagnosis of intraocular retinoblastoma&#xD;
        Failed conventional treatment or conventional therapy is not available Measurable disease&#xD;
        by MRI, CT scan, biochemical tumor markers, cytology, or bone marrow examination&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: Not specified Performance status: Lansky 60-100% OR Karnofsky&#xD;
        60-100% Life expectancy: At least 6 weeks Hematopoietic: Absolute neutrophil count at least&#xD;
        750/mm3 (between 300-750/mm3, if due to bone marrow infiltration by malignancy) Platelet&#xD;
        count at least 75,000/mm3 (between 20,000-75,000/mm3, if due to bone marrow infiltration by&#xD;
        malignancy) Hepatic: Bilirubin less than 2.0 mg/dL ALT less than 3 times upper limit of&#xD;
        normal (ULN) Renal: Creatinine less than 2 times ULN OR Creatinine clearance at least 70&#xD;
        mL/min Neurologic: No peripheral neuropathy grade 3 or 4 No seizure disorder in patients&#xD;
        without CNS malignancies Other: Not pregnant or nursing Negative pregnancy tests during&#xD;
        study and for 1 month after final dose of thalidomide Fertile patients must use effective&#xD;
        contraception during and for at least 1 month after study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: See Disease Characteristics No limit on the number of prior&#xD;
        agents or regimens received Biologic therapy: Prior bone marrow transplantation allowed&#xD;
        Chemotherapy: Recovered from prior chemotherapy No prior thalidomide Endocrine therapy: Not&#xD;
        specified Radiotherapy: Not specified Surgery: At least 4 weeks since prior major surgery&#xD;
        (2 weeks for minor surgery, excluding central venous catheter placement procedures)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ira Dunkel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2004</study_first_posted>
  <last_update_submitted>June 24, 2013</last_update_submitted>
  <last_update_submitted_qc>June 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2013</last_update_posted>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

